



AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-10. (Cancelled)

11. (Currently amended) A compound of the formula:



and pharmaceutically acceptable salts thereof,
wherein n, R¹, R², R³, R⁴, R⁵ and R⁶ are chosen such that the compound is selected from the group consisting of:

- N-(5-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-methyl-hydroxylamine;
- N-(5-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)- hydroxylamine;

- N-(5-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-propyl-O-ethyl-hydroxylamine;
- N-(5-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-methyl-hydroxylamine;
- N-(5-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-ethyl-hydroxylamine;
- N-(5-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-propyl-O-ethyl-hydroxylamine;
- N-(5,6-dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-methyl-hydroxylamine;
- N-(5,6-dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-ethyl-hydroxylamine;
- N-(5,6-dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-propyl-O-ethyl-hydroxylamine;
- N-(5,6-dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-butyl-O-ethyl-hydroxylamine;
- N-(5,6-dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-butyl-O-propyl-hydroxylamine;
- N-(5,6-dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-methyl-hydroxylamine;
- N-(5,6-dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-ethyl-hydroxylamine;
- N-(5,6-dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-propyl-O-ethyl-hydroxylamine;
- N-(1-methyl-2-(3-hydroxy-phenyl)-ethyl)-hydroxylamine;
- N-(1-methyl-2-(3-hydroxy-phenyl)-ethyl)-N-methyl-hydroxylamine;
- N-(1-methyl-2-(3-hydroxy-phenyl)-ethyl)-N-propyl-hydroxylamine;
- N-(1-methyl-2-(3,4-dihydroxy-phenyl)-ethyl)-N-propyl-hydroxylamine;

- N-(1-methyl-2-(3-methoxy-phenyl)-ethyl)-N-methyl-hydroxylamine;
- N-(1-methyl-2-(3-methoxy-phenyl)-ethyl)-N-propyl-hydroxylamine;
- N-(1-methyl-2-(3,4-dimethoxy-phenyl)-ethyl)-hydroxylamine;
- N-(1-methyl-2-(3,4-dimethoxy-phenyl)-ethyl)-N-propyl-hydroxylamine;
- N-(5-hydroxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-O-ethyl-hydroxylamine;
- N-(5-methoxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-O-ethyl-hydroxylamine;
- N-(5,6-dihydroxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-O-ethyl-hydroxylamine;
- N-(5,6-dimethoxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-O-ethyl-hydroxylamine;
- N-(5-hydroxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-N-propyl-O-ethyl-hydroxylamine;
- N-(5-methoxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-N-propyl-O-ethyl-hydroxylamine;
- N-(5,6-dihydroxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-N-propyl-O-ethyl-hydroxylamine;
- N-(5,6-dimethoxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-N-propyl-O-ethyl-hydroxylamine;
- N-(2-methyl-3-(3,4-dihydroxy-phenyl)-propyl)-hydroxylamine;
- N-(2-methyl-3-(3,4-dihydroxy-phenyl)-propyl)-O-ethyl-hydroxylamine;
- N-(2-methyl-3-(3,4-dihydroxy-phenyl)-propyl)-N-methyl-hydroxylamine;

- N-(2-methyl-3-(3,4-dihydroxy-phenyl)-propyl)-N-propyl-hydroxylamine;
- N-(2-methyl-3-(3,4-dihydroxy-phenyl)-propyl)-N-propyl-O-ethyl-hydroxylamine;
- N-(2-methyl-3-(3,4-dimethoxy-phenyl)-propyl)-hydroxylamine;
- N-(2-methyl-3-(3,4-dimethoxy-phenyl)-propyl)-O-ethyl-hydroxylamine;
- N-(2-methyl-3-(3,4-dimethoxy-phenyl)-propyl)-N-methyl-hydroxylamine;
- N-(2-methyl-3-(3,4-dimethoxy-phenyl)-propyl)-N-propyl-hydroxylamine;
- N-(2-methyl-3-(3,4-dimethoxy-phenyl)-propyl)-N-propyl-O-ethyl-hydroxylamine; and
the pharmaceutically acceptable salts thereof.

~~n is 0, 1 or 2;~~

~~R¹ and R², independently of each other, are H, OH or~~
~~CH₃;~~

~~R³ is H or CH₃;~~

~~R⁴ is H, C₁-C₃ straight or branched alkyl or, together~~
~~with R³, forms a five to seven membered carbocyclic ring;~~

~~and R⁵ and R⁶, independently of each other, are H or C₁-~~
~~C₅ straight or branched alkyl~~

~~with the provisos that:~~

~~R¹ and R² cannot be both hydrogen;~~

~~when n is 0, R¹ and R² are both hydroxyl, and R³ and R⁵~~
~~are hydrogen, R⁴ cannot be CH₃;~~

~~when n is 0, R³ is H and R⁴ is H or CH₃, R⁶ cannot be~~
~~C₁-C₃ straight or branched alkyl;~~

~~and that the compound cannot be:~~

- ~~1-(4-hydroxyphenyl)-2-hydroxyaminoethane,~~
- ~~1-(4-hydroxyphenyl)-2-hydroxyaminopropane,~~

~~• 1 (4 methoxyphenyl) 2 hydroxylaminopropane,~~
~~• 1 (3,4 dimethoxyphenyl) 2 hydroxylaminopropane,~~
~~• 1 (4 methoxyphenyl) 4 hydroxylaminobutane~~
~~• 1 (3 methoxyphenyl) 2 hydroxylaminopropane,~~
~~• 1 (3,4 dimethoxyphenyl) 2 hydroxylaminoethane,~~
~~• N methyl 1 (3,4 dihydroxyphenyl) 2~~
~~hydroxylaminopropane,~~
~~• 1 (3 methoxy 4 hydroxyphenyl) 2~~
~~hydroxylaminopropane,~~
~~• N methyl 1 (3 methoxy 4 hydroxyphenyl) 2~~
~~hydroxylaminopropane,~~
~~• N methyl 1 (3,4 dimethoxyphenyl) 2~~
~~hydroxylaminopropane, or~~
~~— one in which, when n is 0, R² is OH and R¹, R³, R⁴~~
~~and R⁶ are H and R⁵ is ethyl.~~


12. (Cancelled)

13. (Previously presented) A pharmaceutical composition comprising one or more compounds according to claim 11 in a mixture with suitable excipients and/or carriers.

14. (Previously presented) A pharmaceutical composition comprising one or more compounds according to claim 11 and a compound for the treatment of central and peripheral nervous system disorders involving protein misfolding and/or misaggregation of beta-amyloid peptide, alpha-synuclein, prion

protein and huntingtin selected from Alzheimer's Disease, Lewy body disease, Parkinson's Disease, spongiform encephalopathies, Huntington's Disease and systemic AA amyloidosis, in admixture with suitable excipients and/or carriers.

15. (New) A compound of the formula:



and pharmaceutically acceptable salts ~~or predrugs~~ thereof, wherein:

n is 0, 1 or 2;

R¹ and R², independently of each other, are H, OH or OCH₃;

R³ is H or CH₃;

R⁴ is H, C₁-C₃ straight or branched alkyl or, together with R³, forms a five to seven-membered carbocyclic ring;

and R⁵ and R⁶, independently of each other, are H or C₁-C₅ straight or branched alkyl

with the provisos that:

R¹ and R² cannot be both hydrogen;

when n is 0, R¹ and R² are both hydroxyl, and R³ and R⁵ are hydrogen, R⁴ cannot be CH₃;

when n is 0, R³ is H and R⁴ is H or CH₃, R⁶ cannot be C₁-C₃ straight or branched alkyl;

and that the compound cannot be:

- 1-(4-hydroxyphenyl)-2-hydroxylaminoethane,
- 1-(4-hydroxyphenyl)-2-hydroxylaminopropane,
- 1-(4-methoxyphenyl)-2-hydroxylaminopropane,
- 1-(3,4-dimethoxyphenyl)-2-hydroxylaminopropane,
- 1-(4-methoxyphenyl)-4-hydroxylaminobutane
- 1-(3-methoxyphenyl)-2-hydroxylaminopropane,
- 1-(3,4-dimethoxyphenyl)-2-hydroxylaminoethane,
- N-methyl-1-(3,4-dihydroxyphenyl)-2-hydroxylaminopropane,
- 1-(3-methoxy-4-hydroxyphenyl)-2-hydroxylaminopropane,
- N-methyl-1-(3-methoxy-4-hydroxyphenyl)-2-hydroxylaminopropane, or
N-methyl-1-(3,4-dimethoxyphenyl)-2-hydroxylaminopropane.

16. (new) A pharmaceutical composition comprising one or more compounds according to claim 15 in a mixture with suitable excipients and/or carriers.

17. (new) A pharmaceutical composition comprising one or more compounds according to claim 15 and a compound for the treatment of central and peripheral nervous system disorders involving protein misfolding and/or misaggregation of beta-amyloid peptide, alpha-synuclein, prion protein and huntingtin

selected from Alzheimer's Disease, Lewy body disease, Parkinson's Disease, spongiform encephalopathies, Huntington's Disease and systemic AA amyloidosis, in admixture with suitable excipients and/or carriers.